Adherence Analysis: Semaglutide QW Versus Other GLP-1 RAs As a result of the relatively short period of time from the launch of semaglutide QW to the index date, fewer patients receiving semaglutide QW were included in the adherence analysis at both 180 and 360 days ( n = 447 and n = 87, respectively), compared with patients receiving dulaglutide ( n = 17,073 and n = 7280, respectively) (Table 2), liraglutide ( n = 11,996 and n = 6137, respectively), and exenatide QW ( n = 5842 and n = 2683, respectively)
Side effects may include headaches, muscle pains, or slight discomfort around the injection site
doi: 10.1371/journal.pone.0226347 222 LozuponeCCota-GomezAPalmerBELindermanDJCharlsonESSodergrenEet al
In recent years, medical science has made significant strides in addressing erectile dysfunction (ED) through innovative treatments